←Parkinson Disease
Study register · detail Systematic Review · Parkinson Disease · 2022

Cannabis in Parkinson's Disease - the patient's perspective versus clinical trials: a systematic literature review.

Figura et al. ·Neurologia i neurochirurgia polska Impact 1.5
No benefit demonstrated GRADE High 19 citations
Samplek = 7 Studien
Durationunclear
EndpointMotor symptoms
Blindingunklar
DesignSystematic Review
Key finding

Randomised studies show no efficacy of cannabinoids for motor symptoms of Parkinson's disease.

Summary

Systematic review on cannabis in Parkinson's disease; k=7 randomised studies identified. Results do NOT support efficacy of cannabinoids for motor symptoms of Parkinson's disease. Conclusion: currently insufficient data for cannabinoid use in PD patients.

P
PopulationParkinson's patients (randomised studies and patient surveys)
I
InterventionCannabinoids (various substances and applications)
O
OutcomeNo evidence of efficacy for motor symptoms; insufficient data for a recommendation
Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile
Sample size ★★★★★
Blinding —
Effect size No benefit
Citations / year ★★★★★
Authors
Figura M, Koziorowski D, Slawek J
DOI 10.5603/pjnns.a2022.0004↗
Design: Systematic Review
Share
Abstract
Cannabis and cannabinoids are often considered in the treatment of Parkinson's Disease (PD). The purpose of this paper was to perform a systematic review of the available data on cannabis treatment. We aimed to assess randomised trials as well as surveys among patients. We identified 569 papers on PD and cannabinoid treatment. Of these, there were only seven papers featuring randomised trials on the effects of different cannabinoids on PD. The results of these trials did not support the efficacy of cannabinoids in the treatment of motor signs of PD. Based on the available data, we conclude that there is currently insufficient data to support the administration of cannabinoids to PD patients. Larger, randomised studies of cannabis use in PD should be conducted.
Indication
Further studies on Parkinson Disease
All studies →
A Liu et al. · 2024 · Movement disorders
19 citations
Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
No benefit demonstrated RCT

RCT n=61 (CBD/THC n=31, Placebo n=30), 2 Wochen Titration auf finale Dosis 191,8±48,9 mg CBD + 6,4±1,6 mg THC täglich. Primärer Endpunkt motor MDS-UPDRS: Reduktion -4,57 (95% CI -8,11 bis -1,03; p=0,013) in CBD/THC-Gruppe vs. -2,77 (-4,92 bis -0,61; p=0,014) in Placebo; Gruppen-Differenz nicht signifikant: -1,80 (-5,88 bis 2,27; p=0,379). Kein Benefit, möglicherweise verschlechterte Kognition und Schlaf; starker Placebo-Effekt. Nebenwirkungen mild, häufiger in CBD/THC-Gruppe.

10.1002/mds.29768 View study →
A Peball et al. · 2020 · Annals of neurology
118 citations
Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.
Mixed RCT

Phase-II-RCT, n=47 Parkinson-Patienten mit stabiler Motorik aber störenden Non-Motor-Symptoms (NMS, MDS-UPDRS-I ≥4). Open-label Nabilone-Titration (0,25–1 mg 2×/d), dann Randomisierung Responder zu Nabilone vs. Placebo (n=19). Primärer Endpunkt MDS-UPDRS-I nach 4 Wochen: Placebo-Gruppe verschlechterte sich um 2,63 Punkte (95% CI 1,53–3,74, p=0,002), Nabilone-Gruppe nur um 1,00 Punkte (95% CI −0,16–2,16, p=0,280); Differenz 1,63 Punkte (95% CI 0,09–3,18, p=0,030, Effektgröße 0,66). Positive Effekte v.a. auf Angst und nächtliche Schlafprobleme. 77% AEs in Titrationsphase (meist transient), keine schwerwiegenden AEs.

10.1002/ana.25864 View study →
A Koppel et al. · 2014 · Neurology
545 citations
Systematic review: Efficacy and safety of medical Cannabis in selected neurologic disorders [RETIRED]
Mixed Systematische Review

Systematische Review der American Academy of Neurology zu medizinischem Cannabis bei neurologischen Erkrankungen; k=34 Studien (8 Class I). Für Parkinson: Orales Cannabis-Extrakt (OCE) wahrscheinlich ineffektiv zur Behandlung Levodopa-induzierter Dyskinesien. Orale Cannabinoide mit unklarer Wirksamkeit bei nicht-Chorea-bezogenen Huntington-Symptomen, Tourette-Syndrom, zervikaler Dystonie und Epilepsie. Risiko schwerer psychopathologischer Nebenwirkungen ~1%.

10.1212/wnl.0000000000000363 View study →

The impediment to action advances action. — Marcus Aurelius